Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 315 across all filing types
Latest filing 2016-10-19 Investor Presentation
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Presentation to Brokers 28 pages 3.7MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Vectus Biosystems' Vasoactive Intestinal Peptide (VIP) technology, focusing on its application in managing fibrotic diseases, hypertension, cardiovascular and renal disease. It includes scientific background, experimental data, animal study results, toxicology, and current status of drug development. The content is structured with slides, images, and detailed scientific explanations, typical of an investor or scientific presentation. There are no indications of financial statements, regulatory filings, voting results, or legal proceedings. The document is not a report or announcement of a report but rather a detailed presentation of technology and research progress. Therefore, the most appropriate classification is Investor Presentation (IP).
2016-10-19 English
Notice of Annual General Meeting/Proxy Form 12 pages 705.3KB
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and details the date, time, and place of the AGM for Vectus Biosystems Limited. It includes the agenda items such as receiving and considering the Annual Report for the year ended 30 June 2016, election of directors, approval of remuneration report, and approval of share issues to directors. The document also contains proxy information and voting exclusion statements. The content is clearly a notice and explanatory statement for an AGM, not the actual Annual Report or financial statements themselves. It is a communication to shareholders about the meeting and the resolutions to be voted on. Therefore, this document fits the category of AGM Information (AGM-R). The document length is substantial (15,000 characters), consistent with detailed AGM notices and explanatory statements. There is no indication that this is a full Annual Report or other report type, nor is it a simple announcement of a report publication. Hence, the classification is AGM-R with high confidence.
2016-10-16 English
2016 Corporate Governance Statement and Appendix 4G 27 pages 702.4KB
Governance Information Classification · 95% confidence The document is titled 'Corporate Governance Statement' and extensively discusses the company's adherence to corporate governance principles, board responsibilities, committee charters, policies on diversity, continuous disclosure, and other governance-related topics. It references compliance with the ASX Corporate Governance Council’s Principles and Recommendations and details the company's governance practices for the fiscal period ending 30 June 2016. There is no financial data, earnings information, or audit results presented. The content is focused on governance structure, policies, and compliance disclosures, which aligns with the definition of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the actual governance report rather than a brief announcement. Therefore, the appropriate classification is Governance Information (CGR).
2016-09-29 English
Annual Report to shareholders 52 pages 2.1MB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2016' for Vectus Biosystems Limited and contains detailed sections typical of an annual report, including Chairman and CEO Report, Directors' Report, Auditor's Independence Declaration, Consolidated Financial Statements, Notes to Financial Statements, Directors' Declaration, and Independent Auditor's Report. The financial year ended 30 June 2016 is specified, and the document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial data, operational review, and governance information consistent with an official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2016
2016-09-29 English
Ceasing to be a substantial holder 2 pages 137.7KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of ceasing to be a substantial holder under the Corporations Act 2001. It details changes in relevant interests of a substantial shareholder, including dates, share sales, and voting securities affected. This type of filing is a notification of changes in significant share ownership levels, which corresponds to a Major Shareholding Notification. The document is not an annual report, earnings release, or any other financial report but a regulatory notice about shareholding changes.
2016-09-25 English
Preliminary Final Report 9 pages 395.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary Final Report' for the financial year ended 30 June 2016 by Vectus Biosystems Limited. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which provide summarized financial results ahead of the full annual report. The document includes detailed financial statements such as consolidated profit or loss, financial position, changes in equity, and cash flows, indicating substantive financial data. It also references that the full Annual Financial Report will be released later. Given the detailed financial data and the nature of the Appendix 4E as a preliminary final report, this document fits the definition of an Interim / Quarterly Report (IR) rather than a full Annual Report (10-K) or just an announcement. The length (15,000 characters) and content confirm it is a substantive financial report, not merely a publication announcement or certification. Therefore, the appropriate classification is IR (Interim / Quarterly Report). FY 2016
2016-08-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.